Libeli

Chlormadinone acetate, the active ingredient in Libeli, is a combined oral contraceptive presented as an oral tablet for oral use. It is employed to prevent pregnancy and to regulate menstrual cycles in women of reproductive age. The formulation also contains ethinylestradiol, an estrogen component that works synergistically with the progestin to provide reliable contraception and cycle control.

GNH USA supplies Libeli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Libeli, a combined oral contraceptive, is used in hormonal management of reproductive health. - Contraception: provides reliable prevention of pregnancy by inhibiting ovulation and altering cervical mucus. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces dysmenorrhea. - Prevention of functional ovarian cysts: reduces the formation of cysts associated with the menstrual cycle.

Libeli may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects: - Deep vein thrombosis: formation of blood clots in deep veins. - Pulmonary embolism: clot migration to the lungs. - Stroke: cerebrovascular accident due to clotting or hemorrhage.

Before prescribing Libeli, clinicians should consider several precautionary measures to ensure safe use. - Assess thrombotic risk: avoid in women with a history of clotting disorders. - Screen for hypertension: monitor blood pressure regularly during therapy. - Consider smoking status: contraindicated in women over 35 who smoke. - Review hepatic function: use with caution in patients with liver disease. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Libeli can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): markedly reduce contraceptive effectiveness. - Anticoagulants (e.g., warfarin): may increase risk of thrombotic events. - Antiepileptics (e.g., carbamazepine): decrease hormone levels, compromising contraception.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline): may slightly lower absorption of hormones. - Herbal supplements (e.g., St. John’s wort): can reduce plasma concentrations of ethinylestradiol. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may enhance mood‑related side effects.